Kezar Life Sciences said a partial clinical hold on a trial for its zetomipzomib program to treat autoimmune hepatitis has been lifted by the Food and Drug Administration. The FDA lifted the hold ...

An Arcellx cell therapy at the heart of a $325 million partnership with Gilead Sciences is now under an FDA clinical hold after the report of a patient death in a pivotal multiple myeloma study ...

Vyne Therapeutics has given up hopes of resuming a plaque psoriasis trial for its BET inhibitor placed on hold by the FDA, ...

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy ...

US FDA lifts clinical hold on PORTOLA phase 2a trial of Kezar Life Sciences for evaluating zetomipzomib to treat autoimmune hepatitis: South San Francisco, California Friday, July ...

CytoDyn's CEO, Dr. Jacob Lalezari, stated, "We are excited that the clinical hold on leronlimab has been lifted by the FDA. CytoDyn is grateful for the FDA's guidance on our protocol and we are ...

The FDA has lifted one of the two clinical holds placed on Kezar Life Sciences’ zetomipzomib, leading the biotech to speculate on whether to reignite another program for the same drug that remains ...

Vigil Neuroscience (NASDAQ:VIGL) announced Tuesday that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on its ongoing Phase 1 clinical trial for its Alzheimer ...

PepGen (PEPG) announced that the FDA has placed a clinical hold on the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in Duchenne muscular dystrophy, while the open-label Phase 2 CONNECT1-EDO51 study ...

Sarepta (NASDAQ: SRPT) highlighted that the clinical hold is temporary and noted that it is unlikely to impact the timeline of these studies significantly. “We’ll be responding to EMA in the ...

Nurix Therapeutics, a San Francisco-based drugmaker, has announced a partial clinical hold on its phase 1 trial for an experimental drug for lymphoma and leukemia.

FDA lifts hold on North Carolina drug factory one year after maggots found The FDA has lifted a clinical hold on three programs being developed by CARsgen Therapeutics.